Preimplantation Genetic Testing Market Growth with Worldwide Industry Analysis to 2027

Preimplantation genetic testing is the procedure of testing embryos to identify genetic diseases or defects before implantation. This test helps to implant healthy embryo which results in the genetically healthy baby. The test is done to eliminate the risk of structural chromosome abnormalities, Mendelian disorders, etc. However, preimplantation genetic testing also carries various risks such as multiple pregnancy, birth defects, ovarian hyperstimulation syndrome. Hence, researchers are focusing on developing new technology and methods that can minimize all the possible risks related with the preimplantation genetic testing.

Due to the changing lifestyle, increasing number of people are suffering from genetic disorders or diseases. Hence there has been a significant growth in the preimplantation genetic diagnosis. This test is also gaining traction to diagnose minor disabilities and other serious diseases such as cancer. Researchers are also focusing on using innovative techniques for eliminating the possibility of embryo destruction while preimplantation genetic testing.

Request For Report Sample at https://www.factmr.com/connectus/sample?flag=S&rep_id=292

According to the latest report by Fact.MR, the global market for preimplantation genetic testing is expected to experience strong growth. The market is estimated to reach US$ 575.0 million revenue by 2022 end. Due to the increasing awareness of preimplantation genetic testing to avoid genetic disorders, the rise in a number of healthcare providers and healthcare institutes providing preimplantation genetic testing are the influencing factors contributing to the tremendous growth of the preimplantation genetic testing across the globe.

Genetic screening is expected to be the highly preferred test type as compared to genetic diagnosis. Gaining nearly two-third of the share in terms of revenue towards 2017 end, genetic screening is estimated to create more than US$ 100 million incremental opportunity throughout the forecast period.

Among all other end users of preimplantation genetic testing, specialized clinics are expected to experience strong growth. Specialized clinics are estimated to exceed US$ 200 million revenue towards 2022 end. Meanwhile, hospitals are also expected to witness impressive growth throughout the forecast period.

Embryo HLA typing for stem cell therapy is expected to show healthy growth from throughout 2017-2022. Embryo HLA typing for stem cell therapy is estimated to create an incremental opportunity exceeding US$ 70 million during 2017-2022.

Compared to the various other technologies, NGS is expected to be the technology gaining highest revenue share in the global preimplantation genetic testing market. NGS is estimated to exceed US$ 200 million revenue by 2022 end.

The report also profiles companies that are expected to remain active in the expansion of global preimplantation genetic testing market through 2022, which include Agilent Technologies Inc., Abbott Laboratories, CooperSurgical Inc., Oxford Gene Technology IP, Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Genea Limited, Natera, Inc., Rubicon Genomics, Inc., and CombiMatrix Corporation.

Report Overview at https://www.factmr.com/report/292/preimplantation-genetic-testing-market

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.